Modified immune cell or precursor cell thereof

Through CRISPR-mediated GEM gene modification and exogenous TCR/CAR introduction on immune cells, the problem of CAR T cells depletion in the tumor microenvironment is solved, and the killing ability and efficacy of target cells is significantly improved.

CN118995633AActive Publication Date: 2024-11-22SHENZHEN BAY LAB
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411477272.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-22
Publication Date
2024-11-22
Estimated Expiration
2044-10-22

AI Technical Summary

Technical Problem

CAR T cell therapy is ineffective in treating solid tumors, mainly due to T cell dysfunction. The existing technology is difficult to effectively solve the depletion problem of CAR T cells in the tumor microenvironment.

Method used

By performing CRISPR-mediated endogenous GEM gene modification on immune cells or their precursor cells, downregulate GEM gene expression and introduce exogenous TCR or CAR, enhance target cell antigen affinity, resist or slow down cell depletion and dysfunction .

Benefits of technology

It significantly improves the killing ability of CAR T cells to target cells, delays or resists functional exhaustion, enhances immunity to tumors, and improves therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995633A_ABST
    Figure CN118995633A_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biology, and provides a modified immune cell or a precursor thereof comprising an endogenous modification encoding a GEM wherein the modification is capable of down-regulating gene expression of the endogenous GEM; further included are exogenous T cell receptors (TCR) and / or chimeric antigen receptors (CAR), the exogenous T cell receptors (TCR) and / or chimeric antigen receptors (CAR) having affinity for antigens on target cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the biological field, and in particular relates to a modified immune cell or a precursor cell thereof. Background Art

[0002] T cell exhaustion is a differentiation state obtained when T cells are exposed to continuous antigen stimulation in the case of chronic viral infection or in the response to tumors. Failure to eliminate antigens can lead to the gradual loss or disorder of effector function. The signs of T cell exhaustion include reduced effector function, different epigenetic and transcriptional gene features (signature), continuous expression of multiple inhibitory receptors, defective cytokine production, increased chemokine expression and limited proliferation capacity. Examination of genes upregulated in CD8+ tumor infiltrating lymphocytes (TIL) from patients' exhaustion and TIL from mouse models has led to the identification of genes that inhibit tumor immunity, including LAYN, Tox and Gata-3. In addition, genome-wide CRISPR-Cas9 knockout and knock-in screening in mice and human CD8+T cells revealed additional targets for regulating T cell function, such as Mapk14, Dhx37, ZC3H12A, Ptpn2, SOSCS1 and TGFBR2. Importantly, in in vivo models, engineered CAR T cells also acquire an exhausted phenotype upon their entry into the tumor microenvironment (TME), leading to the hypothesis that CAR T cell exhaustion / dysfunction is a major hurdle for CAR T cell therapy.

[0003] Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies, but remains largely ineffective in solid tumors. A major factor leading to reduced efficacy of CAR T cell therapy is T cell dysfunction, and the mechanisms mediating this dysfunction are under investigation. There is a need in the art to find new inducers of exhaustion or dysfunction in CAR T cells, which, when destroyed, will allow the development of even more effective CAR T cell therapies designed for the treatment of solid tumors. The present invention addresses this need. Summary of the invention

[0004] The first aspect of the present invention discloses a modified immune cell or a precursor cell thereof, which comprises an endogenous modification encoding a GEM, wherein the modification is capable of down-regulating the gene expression of the endogenous GEM.

[0005] Further comprising an exogenous T cell receptor (TCR) and / or a chimeric antigen receptor (CAR), wherein the exogenous T cell receptor (TCR) and / or the chimeric antigen receptor (CAR) has affinity for an antigen on a target cell.

[0006] wherein the modification is selected from substitution, insertion or deletion. The modification is processed by at least one of RNA interference, CRISPR system mediation, siRNA or drug induction; The CRISPR system is mediated by CRISPR / Cas9, and the CRISPR system comprises a CRISPR nuclease and a guide RNA.

[0007] wherein the guide RNA comprises a guide sequence that is sufficiently complementary to a target sequence in an endogenous locus encoding a GEM.

[0008] The guide RNA has a nucleic acid sequence as shown in SEQ ID NO: 1-2: sgRNA2: cagcatggacagcgactgcg (SEQ ID NO: 1); sgRNA3:actaccgagtggtgctcata (SEQ ID NO:2); The exogenous TCR is selected from wild-type TCR, high-affinity TCR and chimeric TCR.

[0009] In certain embodiments, an exogenous T cell receptor (TCR) includes an antigen binding domain, a transmembrane domain, and an intracellular domain.

[0010] In certain embodiments, the antigen binding domain is selected from the group consisting of an antibody, a scFv, and a Fab.

[0011] In some embodiments, the exogenous chimeric antigen receptor (CAR) further includes a hinge domain. In some embodiments, the hinge domain is selected from an Fc fragment of an antibody, a hinge region of an antibody, a CH2 region of an antibody, a CH3 region of an antibody, an artificial hinge domain, a hinge including an amino acid sequence of CD8, or any combination thereof.

[0012] In certain embodiments, the exogenous CAR comprises a transmembrane domain selected from the group consisting of an artificial hydrophobic sequence and a transmembrane domain of a type I transmembrane protein, an α, β or ζ chain of a T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154.

[0013] In certain embodiments, the exogenous CAR comprises at least one co-stimulatory domain selected from the group consisting of a co-stimulatory domain of a protein in the TNFR superfamily, CD28, 4-1BB (CD137), OX40 (CD134), PD-1, CD7, LIGHT, CD83L, DAP10, DAP12, CD27, CD2, CD5, ICAM-1, LFA-1, Lck, TNFR-I, TNFR-II, Fas, CD30, CD40, ICOS, NKG2C, and B7-H3. In certain embodiments, the exogenous CAR comprises an intracellular domain, which comprises an intracellular domain selected from the following: the cytoplasmic signaling domain of the human CDζ chain, FcyRIII, FcsRI, the cytoplasmic tail of the Fc receptor, an immunoreceptor tyrosine-based activation motif (ITAM) carrying a cytoplasmic receptor, TCRζ, FcRγ, FcR-β, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b and CD66d.

[0014] The antigen on the target cell is a tumor-associated antigen (TAA).

[0015] The modified cells can resist or mitigate cell function exhaustion and / or dysfunction.

[0016] The modified cells are autologous cells or immune cells derived from induced differentiation of allogeneic pluripotent stem cells or their precursor cells.

[0017] wherein the modified cells are cells isolated from a human subject or induced pluripotent stem cells (iPSCs).

[0018] Wherein the modified cell is a modified T cell.

[0019] The modified T cells are resistant to T cell exhaustion and / or T cell dysfunction. After knocking out the GEM gene, T cells are not prone to functional exhaustion or dysfunction.

[0020] The second aspect of the present invention discloses a method for producing the above-mentioned modified immune cells or their precursor cells, comprising: The original immune cells or their precursor cells are modified, wherein the modification is processed by at least one of RNA interference, CRISPR system mediation, siRNA or drug induction; the modified immune cells or their precursor cells are capable of downregulating one or more polypeptides and / or nucleic acids expressed by endogenous GEM genes; Nucleic acid encoding an exogenous T cell receptor (TCR) and / or a chimeric antigen receptor (CAR) is introduced into the immune cell or its precursor cell, wherein the exogenous TCR and / or CAR comprises an affinity for an antigen on a target cell.

[0021] The polypeptides and / or nucleic acids introduce CRISPR-mediated modifications into endogenous loci encoding GEMs.

[0022] The modification is selected from gene replacement, insertion or deletion.

[0023] The CRISPR system comprises a CRISPR nuclease and a guide RNA; the CRISPR nuclease and the guide RNA comprise a ribonucleoprotein (RNP) complex.

[0024] Nucleic acids encoding exogenous TCR and / or CAR are introduced by viral transduction.

[0025] The viral transduction comprises contacting the immune cell or its precursor cell with a viral vector comprising a nucleic acid encoding an exogenous TCR and / or CAR.

[0026] The viral vector is selected from a retroviral vector, a lentiviral vector, an adenoviral vector or an adeno-associated virus (AAV) vector.

[0027] The third aspect of the present invention discloses the use of the modified immune cells or their precursor cells in the preparation of drugs for treating diseases or disorders.

[0028] The diseases or disorders include cancer, both solid tumors and hematological tumors.

[0029] Wherein the disease or disorder comprises a chronic infection.

[0030] The chronic infection is selected from HIV, EBV, CMV, and LCMV.

[0031] The modified immune cells or their precursor cells include T cells, which include CAR and engineered TCR. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 CD8+ T cell subsets identified by scATAC-seq data.

[0033] Figure 2 Volcano plot from scATAC-seq data showing distinct peaks of chromatin accessibility in PDCD1+ CD8+ T cells, labeled with their involved genes.

[0034] Figure 3 Expression patterns of representative genes in CD8+ T cell subsets are shown (ranked by log2FC from scRNA-seq data).

[0035] Figure 4Chromatin accessibility of GEM loci in different CD8+ T cell subsets is shown.

[0036] Figure 5-6 The results show the anti-tumor effects of two anti-EGFR CAR-T cells in vitro (unpaired two-sided t test). Figure 5 ; CAR2, Figure 6 ) were incubated with ESCC cell lines (KYSE30L, KYSE150L) at E / T ratios of 0.008 and 0.0016 for 4 days and analyzed for cytotoxicity using a luciferase-based cytolysis assay. (E / T, effector / target).

[0037] Figure 7 Representative images showing the killing effect of KYSE150L cells co-cultured with anti-EGFR CAR-T-Ctrl and CAR-T-GEM KO cells. (Scale bar: 100 μm).

[0038] Figure 8 Figure 3 Changes in tumor volume after intravenous injection of anti-EGFR CAR1-T cell GEMKO or Ctrl into mice bearing KYSE150L cell xenograft tumors (unpaired two-sided t-test for each time point). (TGI, tumor growth inhibition. KO: knockout).

[0039] Fig. 9 CAR1-T-ctrl and CAR1-T-GEM KO cells were incubated with KYSE-150L cells for PD1 expression assay by flow cytometry. + and CD39 + Representative line graph of expression.

[0040] Figure 10-11 showed that anti-EGFR CAR-T cells (CAR1, Fig.10 ; CAR2, Fig.11 ) ELISA analysis of secreted TNF-α and IFN-γ (unpaired two-sided t-test). (EGFR CAR-T cells of GEM KO or Ctrl were co-cultured with KYSE-30L cells).

[0041] Fig.12 The proportion of eGFP-positive CAR-T cells in the CAR-T-Ctrl and CAR-T-GEM KO cell populations after co-culture with KYSE-150L cells is shown (unpaired two-sided t-test at each time point). The left figure is CAR1; the right figure is CAR2.

[0042] Fig.13The functional status of GEM KO or Ctrl CAR-T cells after in vitro co-culture with KYSE-150L cells is shown (unpaired two-sided t test). Tn, naive T cells, CD45RO- CCR7+; Tcm, central memory T cells, CD45RO+ CCD7+; Tem, effector memory T cells, CD45RO+ CCR7-; Teff, effector T cells, CD45RO- CCR7-. (CAR1 on the left and CAR2 on the right).

[0043] Fig.14 Figure 2. Gene ontology enriched in GEM KO CD8+ CAR-T cells (CAR2). Gene ontology analysis of RNA-seq data of GEM KO CD8+ CAR-T cells and their counterparts. NES: Normalized enrichment score.

[0044] Fig.15 The middle scatter box plot shows the movement speed of GEM OE CAR-T cells and their corresponding control cells (unpaired two-sided t test).

[0045] Fig.16 Line graph showing the dynamics of movement speed of GEM OE CAR-T cells and their corresponding control cells over 16.5 hours.

[0046] Fig.17 Line graph showing the number of GEM OE CAR-T cells and their corresponding control cells after co-culture with KYSE150 cells.

[0047] Fig.18 The line graphs show the number of KYSE150 cells after co-culture with GEM OE CAR-T cells and their corresponding control cells. *, p<0.05; **, p<0.01; ***, p<0.001; ns, not significant.

[0048] Fig.19 Shown is the correlation between GEM expression and PDCD1 expression in PDCD1+ CD8+ T cells in the scRNA-seq dataset (Pearson correlation test). Cells with GEM expression > 0 and PDCD1 expression > 0 were used in the calculation.

[0049] Fig. 20 Shown is the correlation between GEM and PDCD1 expression normalized to CD8A expression in ESCC patients in the TCGA dataset and in-house bulk RNA-seq data.

[0050] Fig.21The correlation between GEM and PDCD1 expression in the spatial transcriptional spots of CD8+ cells with CD8A expression > 0, GEM expression > 0, and PDCD1 expression > 0 is shown (Pearson correlation test).

[0051] Fig. 22 Dot plots showing representative gene expression patterns of CD8+ T cell subsets in the integrated ESCC scRNA-seq dataset.

[0052] Fig.23 Shown are the expression levels of GEMs in the T cell scRNA-seq dataset from the Pan-Cancer Public Database (cohort 7).

[0053] Fig.24 Shown are the efficiency of GEM OE detected by flow cytometry (left) and qPCR (right). OE, overexpression.

[0054] Fig.25 The expression levels of PD1 and CD39 upon restimulation of GEM OE and Ctrl T cells are shown.

[0055] Fig.26 Anti-EGFR CAR1-T cells transfected with GEM OE or Ctrl were shown to secrete TNF-α and IFN-γ. Anti-EGFR CAR1-T cells transfected with GEM OE or Ctrl were cultured with KYSE30L, KYSE150L, ​​and KYSE450L cells, and the concentrations of IFN-γ and TNF-α in the culture supernatants were analyzed by ELISA.

[0056] Fig. 27 Shown are the cell proliferation of ESCC cells (upper panel, KYSE450; lower panel, KYSE150) co-cultured with medium only (blank), T cells, CAR1-T ctrl cells, or CAR1-T GEM OE cells (E / T = 0.2).

[0057] Fig.28 Shows the knockout efficiency of GEMs as determined by TIDE, Tracking of Indels by Decomposition, a web tool for determining allele frequencies.

[0058] Fig.29 Shown are the proliferation of Ctrl CAR-T cells and GEM KO CAR-T cells after culture with KYSE150L cells (unpaired two-sided t test was performed at each time point). Top, CAR1; bottom, CAR2.

[0059] Fig.30 Shown are the protein levels of CCR7 and CD45RO in GEM KO or CtrlCAR-T cells after coculture with KYSE150L cells evaluated by flow cytometry.

[0060] Fig.31 The expression of GEM in CAR-T cells (CAR2) after different rounds of co-culture (Round_0 to Round_2) with ESCC cells KYSE150 is shown by qPCR. Round_0, before co-culture with KYSE150L. Round_1 and 2, co-culture with KYSE150L. Left, qPCR detection of GEM expression. Right is the corresponding cell lysis efficiency of GEM KO CAR-T cells in round 2.

[0061] Fig.32 Shown is the mRNA levels of ZFP36 and ZNF683 in GEM KO CD8+ CAR-T cells (CAR2) and their counterparts investigated by RNA-seq (PFKM).

[0062] Fig.33 Shown is the efficiency of GEM OE detection by qPCR. OE, overexpression.

[0063] Fig.34 The movement trajectories (white lines) of GEM-overexpressing CAR-T cells (CAR2) and their corresponding cells (red) co-cultured with KYSE150 cells (purple) are shown.

[0064] *, p<0.05; **, p<0.01; ***, p<0.001; ns, not significant. DETAILED DESCRIPTION

[0065] Modified immune cells The present invention provides modified immune cells or their precursors (e.g., T cells) comprising endogenous modifications to GEM. In certain embodiments, the cell comprises a nucleic acid capable of down-regulating the gene expression of endogenous GEM. In certain embodiments, the cell further comprises exogenous TCR and / or CAR.

[0066] In one aspect, the present invention provides modified immune cells or their precursors (e.g., T cells) and exogenous CAR, and the modified immune cells or their precursors (e.g., T cells) are included in the CRISPR-mediated modification in the endogenous locus encoding GEM, and the modification can down-regulate the gene expression of endogenous GEM. On the other hand, the present disclosure provides modified immune cells or their precursors (e.g., T cells) and exogenous TCR, and the modified immune cells or their precursors (e.g., T cells) are included in the CRISPR-mediated modification in the endogenous locus encoding GEM, and the modification can down-regulate the gene expression of endogenous GEM.

[0067] The TCR and / or CAR comprises an affinity for an antigen on a target cell. Thus, such modified cells have the specificity directed by the TCR and / or CAR expressed therein.

[0068] The present invention provides modified cells of gene editing. In some embodiments, the modified cells of the present disclosure (e.g., modified cells including exogenous TCR and / or CAR) are gene edited to destroy the expression of endogenous loci encoding GEM. In some embodiments, gene-edited immune cells (e.g., T cells) have downregulation, reduction, deletion, elimination, knockout or destruction of endogenous GEM expression.

[0069] Immunotherapy using CAR (chimeric antigen receptor) T cells and TCR redirected T cells have shown variable efficacy in treating cancer patients. One of the main issues limiting their effectiveness is the exhaustion of T cells after sustained stimulation of tumor cells. Exhausted T cells have reduced effector functions, such as cytokine production and cytotoxicity against tumor cells, and they express higher levels of checkpoint inhibitory molecules, such as PD-1 and CTLA-4. PD-1 and CTLA-4 antibodies have been used clinically to treat many types of cancer.

[0070] The modified cells of the present invention are gene-edited to disrupt the expression of additional endogenous genes. For example, the cells can be further edited to disrupt the endogenous PDCD1 gene product (eg, programmed death 1 receptor; PD-1).

[0071] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are selected according to conventional methods and conditions, or according to the product specifications. The raw materials and equipment used in the examples are well known to those skilled in the art, and are all available on the market or easily obtained or prepared.

[0072] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0073] Example 1: sgRNA in vitro transcription (1) Obtaining in vitro transcription template The in vitro transcription template of sgRNA was obtained by PCR, and a T7 promoter was added to the front end during PCR.

[0074] 1) The PCR reaction system is as follows: Ingredient name Dosage (μL) <![CDATA[ddH 2 The]]> 32.5 5×Buffer 10.0 dNTPs (2.5 mM) 4.0 Primer-F (10 μM) 1.0 Primer-R (10 μM) 1.0 Template (px330) (~50 ng / μL) 1.0 Q5 DNA polymerase 0.5 total 50.0 Mix gently and place on PCR instrument for reaction; 2) The PCR reaction procedure is as follows: program Temperature (°C) time Pre-denaturation 98 30 s transsexual 98 10 s annealing 60 10 s extend 72 15 s extend 72 3 min Finish 4 ∞ Steps 2-4 were performed for 30 cycles in total.

[0075] 3) Nucleic acid gel electrophoresis Prepare 2% agarose gel: weigh 2g agarose powder and pour it into a conical flask, measure 100mL 1×TAE and pour it into the conical flask, heat it in a microwave oven until the agarose powder is completely dissolved, wait for it to cool to about 60°C, mix it, pour it on the plate, and insert a small hole comb. Wait until it is completely cooled and hardened before use. (The concentration of agarose gel should be prepared according to the size of the PCR product band. Generally, the larger the product length, the lower the gel concentration, and the smaller the length, the higher the gel concentration) Add 1 μL DNA 10× loading buffer to 3 μL PCR product, mix well and add to the well of 2% agarose gel. Add DNA marker to the well next to the sample group (generally choose the appropriate DNA marker according to the target band size). Run at 140 V for 25 min. After the running is finished, put the gel into 1×TAE with EB for staining for 20 min. Put the gel block into the gel imager for detection. If the band size is correct, proceed to the next step of recovery.

[0076] 4) PCR product recovery (DNA Clean & Concentrator Kits) ① Add 5 times volume of DNA Binding Buffer (1 mL) to 200 μL PCR product and mix gently; ②Insert the Zymo-Spin Column into the Collection Tube, then add the mixed solution from the previous step to the Column, centrifuge at 6000 rpm for 30 s, and discard the waste liquid; ③ Add 500 μL of Washing Buffer to the adsorption column, centrifuge at 12000 rpm for 30 s, and discard the waste liquid. Repeat once. Empty once again, centrifuge at 12000 rpm for 1 min to remove the residual Washing Buffer; ④ Transfer the column to a new 1.5 mL EP tube and leave it in the air for 2 min to further remove the alcohol in the Washing Buffer. Then add 15 μL ddH 2 O (56 °C), incubate at room temperature for 1 min; ⑤ Centrifuge at 12000 g for 1 min to elute the target DNA fragment and detect the concentration.

[0077] (2) sgRNA in vitro transcription In vitro transcription reaction system: Ingredient name Dosage Nuclease-free water Up to 30 μL NTP Buffer Mix 10 μL Template DNA 1.2 μg T7 RNA Polymerase Mix 2 μL total 30 μL Add the above reagents to a 200 μL EP tube, mix gently, then place the EP tube in a PCR instrument and react at 37°C for 16 hours. After the reaction is completed, take out the EP tube, add 2 μL DNase to it, mix gently, place it in a PCR instrument and react at 37°C for 15 minutes.

[0078] (3) sgRNA product recovery (MEGAclear Kit) ① After the in vitro transcription reaction is completed, add 70 μL of Elution Buffer to the system, mix gently, take out 1 μL for running agarose gel, and judge whether the in vitro transcription is successful based on the size and depth of the band. If successful, you can then recover the in vitro transcription product; ② Elution Buffer preheated at 95°C; ③ Transfer 100 μL of the product from the previous step to a 1.5 mL EP tube, add 350 μL of Binding Buffer to the 1.5 mL EP tube, mix gently, then add 250 μL of anhydrous ethanol, mix gently; ④ Transfer the product from the previous step to the recovery column, incubate at room temperature for 1 min, and centrifuge at 6000 g for 30 s; ⑤ Remove the filtrate, add 500 μL Washing Buffer to the recovery column, centrifuge, 12000 g, 30 s, repeat once, and then empty for 1 min; ⑥ Transfer the recovery column to a new RNase-free EP tube, add 50 μL of 95°C preheated Elution Buffer to the center of the recovery column, cover the EP tube cap, incubate at room temperature for 2 min, centrifuge at 13,000 g for 2 min, and measure the product concentration.

[0079] (4) IVT-sgRNA dephosphorylation Reagent name Reagent dosage IVT-sgRNA 40 μg 10×Cutsmart 10 μL Calf intestinal alkaline phosphatase (CIAP) 40 U RNase-free water Up to 100 μL Mix gently and place in a PCR instrument at 37°C for 1 h. Then use MEGAclear Kit to recover sgRNA.

[0080] Example 2. Detection of editing efficiency of CRISPR / Cas9 system (1) Extraction of edited cell genomic DNA 1) Count the cells to be tested, collect the cells as needed, and centrifuge at room temperature, 400 g, for 5 min; 2) Wash the cell pellet once with DPBS and centrifuge at room temperature, 400 g, for 5 min; 3) Remove the supernatant and add cell lysis buffer to the cell pellet according to the cell quantity. 1 μL is required for 1000 cells. Mix well and transfer to a 200 μL EP tube (PCR tube). 4) Place the above 200 μL EP tube on a PCR instrument for lysis, and the lysis program is (50°C, 60 min; 95°C, 15 min; 4°C, +∞); Note: A set of negative CTRL (cells without gene editing) is also required, and this CTRL is required for both subsequent tests.

[0081] (2) PCR amplification of the DNA sequence of the target site; Note: PCR primers F and R are designed about 400 to 800 bp above and below the target site sgRNAs.

[0082] 1) The PCR reaction system is as follows: Ingredient name Dosage (μL) <![CDATA[ddH 2 The]]> 40.8 10×AccuPrime Buffer II 5.0 Primer-F (10 μM) 1.0 Primer-R (10 μM) 1.0 Template 2.0 AccuPrime taq DNA polymerase 0.2 total 50.0 Mix gently and place on PCR instrument for reaction; 2) The PCR reaction procedure is as follows: program Temperature (°C) time Pre-denaturation 95 3 min transsexual 95 30 s annealing X 30 s extend 68 X extend 68 2 min Finish 4 ∞ Steps 2-4 were performed for 35 cycles in total.

[0083] Note: Annealing temperature was set according to PCR primers, GEM, 60°C; The intra-cycle annealing is set according to the length of the PCR product, and the characteristics of AccuPrime taq DNA polymerase are 1min / 1kb.

[0084] 3) Detect PCR products by agarose electrophoresis and judge based on the size of the product band; (3) TIDE analysis 1) Perform Sanger sequencing on the PCR products of the Surveyor assay; 2) Analyze the peak graph of the above sequencing results through the website http: / / tide.nki.nl. The results are as follows Fig. 22 shown.

[0085] Example 3: Isolation of primary T cells from PBMCs (1) Prepare sorting solution: 98% DPBS + 2% FBS (inactivated) + 1 mM EDTA; (2) Use sorting solution to adjust the density of PBMCs to 5e 7 cells / mL and then transferred to a 5 mL flow tube; (3) Add 50 μL / mL of EasySep human T cell Enrichment cocktail to PBMCs, mix gently by pipetting, and incubate at room temperature for 10 min. (4) Vortex the EasySep D Magnetic Particles on an oscillator for 30 seconds to mix thoroughly, add 50 μL / mL of EasySep D Magnetic Particles to the PBMCs, pipette gently to mix, and incubate at room temperature for 5 minutes. (5) Add DPBS to PBMCs to make up to 2.5 mL, mix gently, remove the cap of the flow tube and insert it into the magnet, and incubate at room temperature for 5 min. (6) Pick up the magnet and quickly pour the cell suspension into a new centrifuge tube (stay for 3 seconds, do not shake). The required CD3+ T cells are in the poured liquid; (7) Add 10 mL of DPBS to the poured cell suspension, mix well, take 20 μL of the cell suspension for counting, and centrifuge at 300 g for 10 min at room temperature without brake-off. Resuspend the cells in a T400 according to the cell number and adjust the CD3+ T cell density to 2e 6 cells / mL were transferred to culture dishes or flasks for culture; (8) Take 2e 5 cells flow cytometry to detect CD3+ cell purity (>95%); (9) Activate CD3+ T cells as needed (4e 7 cells require 1 ml Dynabeads Human T ActivatorCD3 / CD28); (10) Place at 37°C, 5% CO 2 Cultivated in environment.

[0086] Example 4. Preparation of CAR-T cells (1) Lenti-EGFR-CAR virus packaging 1) The revived 293T cells were subcultured twice, and when fully grown, they were subcultured into 10 cm dishes at a ratio of 1:2 and placed in an incubator for overnight culture; 2) The next day, when the confluence of 293T cells is about 90%, replace the cells with 7 mL of fresh culture medium preheated at 37°C; 3) Prepare two 15 mL centrifuge tubes A and B; 4) Add Opti-MEM restored to room temperature to tubes AB, 1.5 mL to each tube. 5) Add P3000: 48 μL, packaging plasmid pMD2.G, pasPAX2 6 μg each, and target plasmid fuw-EF1a-019-28Z-P2A-eGFP 12 μg to tube A, and mix gently; 6) Add Lipofectamine 3000: 42 μL to tube B; 7) Incubate tubes A and B at room temperature for 5 min respectively; 8) Add tube A to tube B, mix gently, and incubate at room temperature for 15 min to form liposome-DNA complex; 9) Add the liposome-DNA complex formed after incubation of A+B to the cells in 2) after changing the medium (add slowly and gently from the side of the culture dish to blow off the cells), and then return to 37°C, 5% CO 2 Continue to culture in the incubator; 10) 48 h after transfection, the virus (culture supernatant) was collected and replenished with fresh pre-warmed DMEM complete medium. The cells were returned to 37°C, 5% CO 2 Continue culturing in the incubator, and store the collected cell supernatant at 4°C; 11) 72 hours after transfection, the virus was collected again, and the supernatants collected twice were mixed and filtered with a 0.45 μm filter membrane (to remove the detached cells and cell debris in the supernatant); 12) Virus concentration: add the supernatant after filtration in the previous step to a virus concentration tube (less than 15 mL) and centrifuge at 3200 g for 50 min at 4°C. 13) After centrifugation, a dark red virus concentrate can be seen in the middle of the virus concentration tube, about 200 μL, which can be used immediately or transferred to a 1.5 mL EP tube, sealed with sealing film, and stored at -80°C; (2) Lentivirus infection of T cells 1) 24 hours after T cell activation, the activated cells were counted; 2) Take the required amount of cells and adjust the cell density to 2e 6 / ml; 3) Add the corresponding amount of concentrated lentivirus according to the cell volume. 50μL of concentrated virus solution can infect 1e 6 Add the transfer reagent Polybrene at a final concentration of 10 μg / mL to the cells, mix gently and place in a 6-well plate with a volume of 1 mL per well, and then culture in an incubator; 4) After 4-6 hours of culture, the infected cells were replenished with 1 mL per well and continued to be cultured in the incubator; 5) 48 h after infection, the infection efficiency can be detected by measuring the proportion of eGFP using flow cytometry.

[0087] (3) Preparation of GEM gene knockout CAR-T cells 1) Preparation of experimental reagents Electroporation kit (P3 Primary Cell 4D-Nucleofector X Kit); SpCas9 protein (on ice); sgRNA (on ice); T cell culture medium; DPBS; Loza electroporator; RNase-free EP tube; RNase-free pipette tip (10μL / 200μL / 1mL), etc. 2) Two days after CAR-T cell infection, that is, three days after T cell activation, CD3 + / CD28 + beads; 3) Add sgRNA (6 μg / well) to the RNase-free EP tube, then slowly add SpCas9 protein (6 μg / well), mix gently, and incubate at room temperature for 20 min to form an RNP complex; 4) Prepare electroporation buffer: 20 μL system: 16.4 μL nucleofector solution + 3.6 μL Supplement, mix gently, and place at room temperature for later use (usually prepared immediately before use); 5) During the incubation period of sgRNA and cas9 protein, prepare cells ① Cell counting, take out cells according to the amount of cells to be electroporated, 1e per electroporation well6 cells (generally take more than 0.5 samples), centrifuge: 300 g, 10 min, room temperature, speed up and down without brake (brake-off); ② Remove the supernatant, add 5 ml DPBS, blow evenly, and centrifuge: 300 g, 10 min, room temperature, without brake-off (the purpose is to wash away the FBS in the culture medium); 6) After the cells are centrifuged, remove the supernatant (try to remove as much of the supernatant as possible without aspirating the cells), resuspend the cell pellet with the prepared electroporation buffer, mix gently, and add it to the RNP incubated in (4), mix gently, transfer it to the wells of the electroporation strip (do not generate bubbles), and tap the bottom gently to ensure that the cell suspension is at the bottom of the electroporation well; 7) Place the electroporation strip into the electroporator and operate the electroporation procedure: EO-115 program; 8) After electroporation, remove the electroporation strip and add 80 μL of preheated T cell culture medium to each electroporation well in the clean bench. Cover the electroporation strip and place it in the incubator for 20 minutes. 9) Transfer the cells from the electroporation strip to a 12-well plate, add 1 mL of T cell culture medium, and incubate at 37°C, 5% CO 2 Culture in incubator.

[0088] Example 5. CAR-T cell killing experiment in vitro 1) Adjust the cell density of target cell KYSE150-luc to 1e using 1640 complete medium. 5 cells / mL, and after mixing, the cell suspension was seeded in a 96-well plate, 100 μL per well, and each effector cell and target ratio were replicated 3 times; 2) According to the killing effector-target ratio, the effector CAR-T / T cells are added to the target cells in a certain ratio, with a final volume of 200 μL; 3) Place the cells in an incubator and culture them, and test the killing efficiency at the corresponding time points; 4) Add 10uL of Steady-Glo luciferin substrate to each well and react for 5 min. Detect the fluorescence value after the reaction of luciferase and substrate using an ELISA reader.

[0089] 5) Calculate the killing efficiency of effector cells on target cells based on the fluorescence value of each well: specific lysis (%) = (1-RUL effector cells plus target cells / RUL target cells) * 100 (RUL: relative light unit). The results are as follows Figure 5-6 shown.

[0090] Example 6: ELISA detection of cytokine release Collection of supernatant 1) Effector cells to target cells 0.04:1 (1e per cell) 4 ) ratio, 200 μL of the system was placed in a 96-well plate and incubated for 2 days. The culture medium used during incubation was 1640 complete medium; 2) After 2 days of incubation, collect the supernatant for detecting IFN-γ, TNF-α and grazmB released when the effector cells react with the target cells. The supernatant can be used immediately or stored at -80°C. 3) Cytokine test results such as Figure 10-11 shown.

[0091] Example 7: Multiple rounds of killing experiments 1) 3e 5 CAR-T cells were incubated with tumor cells at a 1:1 ratio.

[0092] 2) Two days later, all tumor cells were lysed, and the CAR-T cells were collected and counted, and then incubated with tumor cells again at a ratio of 1:1. And so on, new tumor cells were added every 2 days until the lysis ability of CAR T cells was significantly reduced.

[0093] 3) At the end of each round, CAR-T cells were collected and relevant parameters were measured by flow cytometry. Fig. 9 shown.

[0094] Example 8 CAR T cells were cultured with KYSE150 tumor cells. CD8+GFP+ effector cells were isolated by fluorescent cell sorting after co-incubation in Round_3. Samples were sent to GENE DENOVO Ltd. (Guangzhou, China) for RNA extraction, library preparation, and sequencing.

[0095] Plasmid construction Fuw-EF1α-CARs-P2A-eGFP (anti-EGFR CAR1 and CAR2) was constructed in this example, and other plasmids were modified on this basis. Fuw-EF1α-CARs was obtained by removing [P2A-eGFP] from Fuw-EF1α-CARs-P2A-eGFP, and Fuw-EF1α-P2A-mcherry and Fuw-EF1α-GEM-P2A-mCherry plasmids were obtained by replacing the [CAR2-P2A-eGFP] gene with [P2A-mcherry or GEM-P2A-mcherry] from Fuw-EF1α-CAR2-P2A-eGFP.

[0096] Lentivirus production HeK293T cells were cultured at 7×10 per 10 cm2. 6 The number of cells was seeded, and the cell transfection experiment was performed when the cell confluence reached about 90% after 15 to 18 hours. The transfection process was carried out according to the instructions of Lipo3000 (Thermo Fisher, L3000015). At 48 hours and 72 hours after transfection, the viral supernatant was harvested and filtered with a 0.45 mm filter. Then, the lentiviral particles were concentrated by centrifugation at -4°C and 4000 rcf (Merck Millipore Ultracel-100 K, UFC910096) for 1 hour; finally, the concentrated virus was stored at -80°C.

[0097] Isolation, activation and expansion of CD3+ T cells Peripheral blood mononuclear cells (PBMCs) were purchased from Milestone Biotechnologies. T cells were isolated using the EasySep Human T Cell Enrichment Kit (Stemcell Technologies) and activated and expanded with anti-CD3 / anti-CD28 Dynabeads magnetic beads (Thermo Fisher Scientific) at a 1:1 ratio according to the manufacturer's instructions. T cells were cultured in X-VIVO15 medium (Lonza) supplemented with 5% (v / v) heat-inactivated FBS (GIBCO) and 400 IU / mL recombinant human IL-2 (Sino Biological, Inc.) Construction of anti-epidermal growth factor receptor CAR The scFv is derived from the epidermal growth factor receptor antibody mAB806, which recognizes residues 287-302 of the epidermal growth factor receptor. The anti-EGFR CAR contains the extracellular domain of the human CD8a signal peptide (nucleotides 1032-1094; GenBank NM 001145873.1), the CD8a hinge (nucleotides 1443-1577; GenBank NM001145873.1), and the CD28 transmembrane domain (nucleotides 515-595; GenBank NM 006139.4). The CD28 ("28"; nucleotides 596-718, GenBank NM 006139.4) costimulatory domain and CD3z ("Z"; nucleotides 363-698, GenBank XM 011510145.2) costimulatory peptide constitute the intracellular domain of the anti-EGFR CAR. In order to facilitate the detection of the efficiency of CAR in T cells infected by anti-CAR lentivirus, the "self-cleaving" peptide P2A and eGFP were connected behind CD3Z. All anti-CAR sequences were chemically synthesized and constructed into lentiviral vectors.

[0098] Generation of anti-EGFR CAR-T cells Freshly purified primary CD3+ T cells were activated with Dynabeads Human T-Activator CD3 / CD28 (LifeTechnologies) at a 1:1 ratio for 24 h and then infected with lentivirus carrying anti-EGFR CAR. The density of T cells was maintained at 2×10 6 cells / ml.

[0099] In vitro transcription Preparation of in vitro transcribed (IVT) single guide RNA (sgRNA): Plasmid PX330 (42230) containing the sgRNA backbone was used as a PCR template, and the PCR amplified fragment containing the T7 promoter, 20-bp target sequence, and sgRNA backbone was obtained and used as an IVT template. IVT was performed using the MEGAshortscript T7 Kit (Thermo Fisher Scientific). For treatment, 2 U of calf intestinal phosphatase (NEB) was added per microgram of in vitro transcribed sgRNA, followed by incubation at 37°C for 1 hour. The sgRNA was then purified using a MEGAclear column (ThermoFisher Scientific) and eluted with elution buffer.

[0100] Example 9 Analysis of gene editing and overexpression efficiency CAR-T cells were collected 72 hours after electroporation for Sanger sequencing (GENE DENOVO Ltd. Guangzhou, China). The genomic knockout level of GEM in CAR-T cells was determined by TIDE (Tracking Indels by Decomposition) analysis. The expression level of GEM was detected by qPCR. Total RNA was extracted using RNAmini Kit (Qiagen) according to the manufacturer's instructions. cDNA was synthesized by reverse transcription using HiScriptII 1st Strand cDNA Synthesis Kit (Vazyme). GEM mRNA was quantified using CFX96 Real-Time Detection System (Bio-Rad) and ChamQ SYBR qPCR Master Mix (Vazyme). Genotyping PCR primers used to amplify the target loci were as follows: human GEM forward: gtgtccagttgaaagcctgtc, reverse: cctttctggcccaggatcaac. The qPCR primers used to detect GEM and GAPDH expression were as follows: Human GEM forward: aagctggtcctctgactcca, reverse: cactttccccatcaaccatc. Human GAPDH forward: atgacatcaagaaggtggtg, reverse: cataccaggaaatgagcttg.

[0101] Example 10 Electroporation of CAR-T cells CRISPR / Cas9 gene editing was performed by electroporating Cas9 / gRNA (RNP) complexes using 4D-Nucleofector (Lonza) and PrimaryCell 4D-NucleofectorTM X Kit S (V4XP-3032, Lonza). RNPs contained 10 μg Cas9 protein and 10 μg sgRNA (human GEM sgRNA1: cagcatggacagcgactgcg; sgRNA2: actaccgagtggtgctcata) and were pre-complexed at room temperature for 15 min to form ribonucleoprotein complexes. 1×10 6CAR-T cells were centrifuged at 300 rcf for 6 minutes and then resuspended in 20 μL of transfection buffer. RNPs were also resuspended in 20 μL of the above transfection buffer. The mixture was then transferred to the electroporation cuvette of a 16-well cuvette strip using the EO-115 program. CAR-T cells were revived in 1 mL of pre-warmed T cell culture medium and expanded as described above. Gene knockout efficiency was detected using the decomposition indole tracking technology (TIDE), and the results are shown in Fig.28 shown.

[0102] Example 11 Multiple rounds of antigen stimulation test CAR-T cells (3×10 5 ) were co-incubated with KYSE150 tumor cells at a 1:1 effector to target cell (E / T) ratio. After two days, all tumor cells were lysed, and then new tumor cells were added to the culture system. Similarly, new tumor cells were added every two days until the lysis ability of CAR-T cells was significantly reduced. CAR-T cells were collected after each round of culture, and relevant parameters were measured by flow cytometry.

[0103] Example 12 Flow cytometry Fluorescence expression analysis was performed using CytoFLEX LX (Beckman Coulter) and BD LSRFortessa. Cell harvesting and preparation were performed according to the manufacturer's protocol.

[0104] Example 13 Luciferase-based cell lysis assay Cytotoxicity assessment of KYSE450-luciferase KYSE150-luciferase cells and KYSE30-luciferase cells was performed as described above. Luciferase cells were cultured at 4 × 10 4 The cells were suspended in RPMI 1640 medium at a density of 10 cells / mL. 100 μL of the cell suspension was inoculated into 96 white opaque plates and incubated at 37°C with 5% CO 2 After 8 hours, 100 μL of CAR-T cell suspension was inoculated into tumor cells at the specified ratio and cultured at 37°C and 5% CO 2The cells were cultured for 2 or 4 days under the same conditions. Ten microliters of Steady-Glo luciferase substrate (Promega) was added, and luminescence was recorded 5 minutes later using a Synergy H1 imager (Bio Tek). The results were reported as percent killing based on the comparison of luciferase activity in the wells with that in the wells containing tumor cells alone, where percent killing = 100-[(RLU of wells containing co-culture of effector and target cells) / (RLU of wells containing target cells) × 100].

[0105] Example 14 Cytokine ELISA At a ratio of 0.4:1 (4×10 3 The effector cell supernatant was harvested after 48 h of co-incubation with target tumor cells (KYSE150, KYSE450, and KYSE30). The cytokines produced by the effector cells, including IFN-γ, TNF-α, and Granzyme B, were evaluated by ELISA kits according to the manufacturer's protocol.

[0106] Example 15 Animal Model and In Vivo CAR-T Cell Functional Detection Six-week-old female NOD-Prkdcscid Il2rgem1 / Cyagen (C-NKG) mice (Cyagen) were injected subcutaneously with 2×10 6 KYSE150-luci tumor cells. The mice were randomly divided into two groups: CAR1-Ctrl and CAR1-GEM KO (n = 4 in each group); when the tumor volume was about 60 mm 3 At 1 pm, mice were injected once with 5 × 10 5 CAR-T cells. Body weight and tumor size were monitored every 4 days. The tumor volume was calculated as V = 0.52×L×W 2 (V, volume; L, tumor length; W, tumor width). The formula for calculating tumor growth inhibition rate is TGI = (1-ΔT / ΔC) × 100%, where ΔT = the change in tumor volume of the drug treatment group on the last day of the study, and ΔC = the change in tumor volume of the control group on the last day of the study.

[0107] Example 16 Live Cell Time-lapse Imaging KYSE150 cell lines expressing tagBFP-H2B and halo-TM (147 bp PDGFRB transmembrane sequence) were incubated with Janelia Fluor® HaloTag® ligand (1:1000, Sigma-Aldrich, GA1120) at 37°C for 15 minutes. After incubation, the cells were resuspended in complete RPMI 1640 medium at a concentration of 1.5 × 10^5 cells / mL, and then 100 μL of cells were seeded into 96-well glass-bottom culture plates (Cellvis, P96-1.5HN) per well and incubated at 37°C with 5% CO. 2 After 6 hours, effector CAR-T cells expressing mCherry and overexpressing GEM and their corresponding cells were added to each well at different effector cell to tumor cell (E / T) ratios (1:1.5), and 100 μL of cell suspension was added to each well.

[0108] To investigate the movement speed and deformation of CAR-T cells when targeting tumor cells, the co-cultures were placed in a benchtop mini-incubator equipped with a humidifier and time-lapse imaging was performed under the same conditions. Fluorescence time-lapse experiments were performed using a SpinSR (Olympus) microscope and a 40x air objective (NA0.95). The imaging process included layer scanning (9.4 μm in total, 1 μm interval) and the use of optimized filter sets: B447 / 60nm (405nm) for mTagBFP, B617 / 73nm(561nm) for mCherry, and B685 / 40nm (640nm) for halo-tag. Image analysis including 3D reconstruction, single cell tracking, and quantification of CAR-T cell and tumor cell behavior—such as the number of interactions and distance from the tumor—was performed using the point and surface modules in Imaris10.1.0 (Imaris). These modules also facilitated further analysis of the speed of contacting cells.

[0109] To analyze the dynamic interactions of CAR-T cells with tumor cells during contact and killing of tumor cells, an Opera Phenix Plus (PerkinElmer) microscope equipped with a 20× water objective (NA 1.0) was used. The solid-state filters of the microscope (435 / 550nm, 570 / 630nm, and 650 / 760nm) were used to detect the designated fluorescence channels. The imaging process involved layer scanning arranged in a 1×5 pattern (9 μm in total, 1 μm interval). The resulting images were projected using the maximum intensity projection method, and single-cell level analysis was performed using the microscope's integrated software. Data visualization was performed using Prism 10 (GraphPad) and Origin (OriginLab Corporation) software. Representative videos and images were produced using Imaris software. The results are shown in Figure 2. Figure 33-34 shown.

[0110] The present invention first focused on exhausted CD8+ T cells, analyzed the expression levels and chromatin accessibility of classic exhausted activation markers, and confirmed the specific expression of CXCL13, LAYN, PDCD1 and TOX in exhausted CD8+ T cells. The inventors unexpectedly found that GEMs encoding small GTP-binding proteins of the Ras superfamily showed both higher expression and chromatin accessibility in exhausted CD8+ T cell subsets ( Figure 2-3 ), and previously, GEM expression and T cell regulation have not been reported. It is worth noting that according to the scATAC-seq and scRNA-seq data of the present invention ( Figure 2-3 ), GEM showed more specific expression in exhausted CD8+ T cell subsets and increased accessibility of its promoter region in this subset compared with LAYN, PDCD1, or TOX ( Fig.16 In addition, GEM showed a weak positive correlation with the expression of PDCD1 in scRNA-seq data (R = 0.15, p = 1.0 × 10 -12 ;See Fig.14 ), compared with the ESCC RNA sequencing data in the TCGA cohort (R = 0.48, p = 1.5 × 10 -6 ;See Fig. 20 , left; R = 0.41, p = 9.5×10 -8 ;See Fig. 20 , right), and spatial transcriptomics data (R = 0.25, p = 6.5 × 10 -8 ;See Fig.21Further validation using public scRNA-seq data from integrated pan-cancer T cells confirmed the specific expression of GEMs in exhausted CD8+ T cells (see Fig.23 ), suggesting that GEM plays an important role in T cell exhaustion.

[0111] To verify that GEMs were involved in T cell exhaustion, the present invention ectopically expressed GEMs in primary T cells from healthy donors ( Fig.24 GEM overexpression (GEM-OE) resulted in increased expression of PD-1 and CD39 after restimulation ( Fig.25 ), indicating the potential role of GEM in T cell exhaustion. Further, CARs were used to determine whether GEM would affect the function of CAR-T cells. The results showed that GEM overexpression reduced the release of IFN-γ and TNF-α and weakened the cytolytic activity against ESCC cells ( Figure 26-27 In contrast, GEM knockout enhanced the cytolytic capacity of CAR-T cells in vitro and in vivo ( Figure 5-8 ), reduced PD-1 and CD39 levels ( Fig. 9 ), increased the secretion of IFN-γ and TNF-α ( Figure 10-11 ), GEM gene knockout also promoted the proliferation of CAR-T cells ( Fig.12 ) and altered their functional status by increasing the proportion of central memory T cells (see Fig.30 ). The present invention also found that the level of GEM mRNA gradually increased with continuous co-culture with tumor cells (Figure 31). The above results show that during tumorigenesis, GEM regulates CD8+ T cells toward a dysfunctional state, so it is possible to enhance the anti-tumor immunity of CAR-T cells by eliminating GEM.

[0112] In order to explore the potential mechanism of GEM gene regulation of CD8+ T cell exhaustion, RNA-seq analysis was performed on GEM gene knockout (GEM-KO) CD8+ CAR-T cells and their counterparts. The results showed that GEM gene knockout could significantly increase the expression of ZNF683 and ZFP36 ( Fig.32 ), both of which are involved in maintaining the response of CD8+ T cells. Similarly, GSEA analysis showed that the anti-tumor inflammatory response pathway was significantly enriched in the GEM-KO group (Figure 14). The immune synapse is a manifestation of the cytolytic function of CD8+ T cells. The results also showed that synapse-related processes and actin cytoskeleton remodeling were prominent in the GEM-KO group (Figure 14), suggesting that immune synapse formation may be enhanced after GEM elimination. It has been previously documented that GEM can inhibit high voltage-activated Ca 2+In the present study, the GEM-KO group also observed a high enrichment of calcium channel complexes related to cytotoxicity to CD8+ T cells (Figure 14). Time-lapse imaging showed that GEM overexpression significantly weakened the motility of CAR-T cells ( Figure 15-16 , Figure 33-34 ), and the ability to bind to and kill target cells ( Figure 17-18 The above findings suggest that GEM may weaken the cytolytic ability of T cells by inhibiting cell motility and the ability to bind to target cells.

[0113] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A modified immune cell or a precursor cell thereof, comprising an endogenous modification encoding a GEM, wherein the modification is capable of downregulating the gene expression of the endogenous GEM.

2. The modified immune cell or its precursor cell according to claim 1 further comprises an exogenous T cell receptor (TCR) and / or a chimeric antigen receptor (CAR), wherein the exogenous T cell receptor (TCR) and / or the chimeric antigen receptor (CAR) has affinity for an antigen on a target cell.

3. The modified immune cell or precursor cell thereof according to any one of claims 1-2, wherein the modification is selected from substitution, insertion or deletion.

4. The modified immune cell or its precursor cell according to any one of claims 1 to 3, wherein the modification is processed by at least one of RNA interference, CRISPR system mediation, siRNA or drug induction.

5. The modified immune cell or precursor cell thereof according to claim 4, wherein the CRISPR system is mediated by CRISPR / Cas9, and the CRISPR system comprises a CRISPR nuclease and a guide RNA.

6. The modified immune cell or precursor cell thereof according to claim 5, wherein the guide RNA comprises a guide sequence that is sufficiently complementary to a target sequence in an endogenous locus encoding a GEM.

7. The modified immune cell or its precursor cell according to any one of claims 5-6, wherein the guide RNA has a nucleic acid sequence as shown in SEQ ID NO: 1-2: sgRNA2: cagcatggacagcgactgcg (SEQ ID NO: 1); sgRNA3: actaccgagtggtgctcata (SEQ ID NO: 2).

8. The modified immune cell or precursor cell thereof according to claim 2, wherein the exogenous TCR is selected from a wild-type TCR, a high-affinity TCR and a chimeric TCR.

9. The modified immune cell or precursor cell thereof according to claim 2, wherein the antigen on the target cell is a tumor-associated antigen (TAA).

10. The modified immune cell or its precursor cell according to any one of claims 1-2, wherein the modified cell can resist or alleviate cell function exhaustion and / or functional disorder. The modified immune cell or its precursor cell according to claim 10 , wherein the modified cell is an immune cell or its precursor cell derived from induced differentiation of autologous cells or allogeneic pluripotent stem cells. 12 . The modified immune cell or a precursor cell thereof according to claim 11 , wherein the modified cell is a cell isolated from a human subject or an induced pluripotent stem cell (iPSC).

13. The modified immune cell or precursor cell thereof according to claim 12, wherein the modified cell is a modified T cell.

14. The modified immune cell or precursor cell thereof according to claim 13, wherein the modified T cell is resistant to T cell exhaustion and / or T cell dysfunction.

15. A method for producing a modified immune cell or a precursor cell thereof as claimed in any one of claims 10 to 14, comprising: Modifying the original immune cells or their precursor cells, wherein the modification is processed by at least one of RNA interference, CRISPR system mediation, siRNA or drug induction; The modified immune cells or their precursor cells are capable of downregulating one or more polypeptides and / or nucleic acids expressing endogenous GEM genes; Nucleic acid encoding an exogenous T cell receptor (TCR) and / or a chimeric antigen receptor (CAR) is introduced into the immune cell or a precursor cell thereof, wherein the exogenous TCR and / or CAR comprises an affinity for an antigen on a target cell.

16. The method of claim 15, wherein the polypeptide and / or nucleic acid is introduced into a CRISPR-mediated modification in an endogenous locus encoding a GEM.

17. The method of claim 15, wherein the modification comprises gene replacement, insertion or deletion.

18. The method of claim 15, wherein the CRISPR system comprises a CRISPR nuclease and a guide RNA; the CRISPR nuclease and the guide RNA comprise a ribonucleoprotein (RNP) complex.

19. The method of claim 15, wherein the nucleic acid encoding the exogenous TCR and / or CAR is introduced by viral transduction.

20. The method of claim 19, wherein the viral transduction comprises contacting the immune or precursor cells thereof with a viral vector comprising a nucleic acid encoding an exogenous TCR and / or CAR.

21. The method of claim 20, wherein the viral vector is selected from a retroviral vector, a lentiviral vector, an adenoviral vector or an adeno-associated virus (AAV) vector.

22. Use of the modified immune cell or its precursor cell according to any one of claims 1 to 14 in the preparation of a drug for treating a disease or disorder.

23. The use according to claim 22, wherein the disease or disorder comprises cancer, and the cancer comprises solid tumors and blood tumors.

24. The use according to claim 22, wherein the disease or disorder comprises a chronic infection.

25. The use according to claim 24, wherein the chronic infection is selected from HIV, EBV, CMV, LCMV.

26. The use according to claim 22, wherein the modified immune cells or their precursor cells include T cells, and the T cells include CAR and engineered TCR.

Citation Information

Patent Citations

  • Small ribonucleic acid interference molecule for specifically inhibiting NK (Natural Killer) cell receptor KIR3DL1 and application of small ribonucleic acid interference molecule

    CN102911940A

  • Modified immune cells having enhanced function and methods for screening for same

    CN112204148A

  • Systems and methods for enhanced immunotherapy

    CN114981415A

  • Modified immune effector cells and methods of use

    WO2024178397A2